- Home
- AMZE vs NXL Comparison
AMZE vs NXL Comparison
Compare AMZE & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- NXL
- Stock Information
- Founded
- AMZE 2019
- NXL 2010
- Country
- AMZE United States
- NXL United States
- Employees
- AMZE N/A
- NXL N/A
- Industry
- AMZE Beverages (Production/Distribution)
- NXL Medical Specialities
- Sector
- AMZE Consumer Staples
- NXL Health Care
- Exchange
- AMZE Nasdaq
- NXL Nasdaq
- Market Cap
- AMZE 16.1M
- NXL 14.0M
- IPO Year
- AMZE 2021
- NXL 2022
- Fundamental
- Price
- AMZE $2.12
- NXL $0.85
- Analyst Decision
- AMZE
- NXL Strong Buy
- Analyst Count
- AMZE 0
- NXL 1
- Target Price
- AMZE N/A
- NXL $5.00
- AVG Volume (30 Days)
- AMZE 75.3K
- NXL 2.9M
- Earning Date
- AMZE 08-14-2025
- NXL 08-06-2025
- Dividend Yield
- AMZE N/A
- NXL N/A
- EPS Growth
- AMZE N/A
- NXL N/A
- EPS
- AMZE N/A
- NXL N/A
- Revenue
- AMZE $1,054,111.00
- NXL $174,813.00
- Revenue This Year
- AMZE $6,741.66
- NXL $38.28
- Revenue Next Year
- AMZE $100.61
- NXL $185.71
- P/E Ratio
- AMZE N/A
- NXL N/A
- Revenue Growth
- AMZE N/A
- NXL 16.42
- 52 Week Low
- AMZE $2.00
- NXL $0.59
- 52 Week High
- AMZE $28.72
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- AMZE 29.59
- NXL 46.03
- Support Level
- AMZE $2.35
- NXL $0.78
- Resistance Level
- AMZE $3.28
- NXL $0.99
- Average True Range (ATR)
- AMZE 0.28
- NXL 0.12
- MACD
- AMZE 0.07
- NXL 0.01
- Stochastic Oscillator
- AMZE 9.49
- NXL 28.03
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.